A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

Summary

An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.

Timeline

Start

2010-03

Primary completion

2012-05

Completion

2012-05

Outcome

Missed primary endpoint

paper Neither LY2140023 dose showed significant improvement compared to placebo on PANSS total in either population PMID 25539791 ↗

Publications

• Background [APA] American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. Washington DC: American Psychiatric Association; 2000.
• Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19.
• Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, Brenner R, Rayle TJ, Nisenbaum L, Zhao F, Gomez JC. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014 Dec 10;14:351. doi: 10.1186/s12888-014-0351-3.

Drugs

Indications